-
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
— 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate — —
Lifestyle Content
Technology
-
Freddy Will Named Content Creator of the Year at the Influencer Magazine Awards 2026
-
D. B. Minter Explores Opera, Desire and Identity in ‘The Little Red Book’
-
BEYONCÉ TAKES CENTER STAGE IN NEW USC MARSHALL MBA COURSE
-
Former FBI Agent Exposes Systemic Bias in Gripping New Memoir
-
SPOZZ Brings Automated Karaoke Production to Direct-to-Fan Music
Entertainment
-
Horse Gelatin Recipe For Men and Horse Gelatin Trick: 2026 Review Finds No Controlled Human Trials Behind Viral Claims
-
Hema Balance Blood Optimizer Review: Publishes Ingredient Dose Comparison for Blood Optimizer Capsule, 917,800 Bottles Sold
-
Sustainable Medical Billing Acquires Impact Healthcare Solutions
-
Ascension Recovery Services Awarded $1.5 Million to Help West Virginians in Recovery Return to Work
-
Ibogaine Club Research Group Submits Detailed Public Comment to FDA on Ibogaine Clinical Trial Design and Safety
